文献速递泌尿生殖与妇科肿瘤放疗

多机构分析:单纯阴道近距离放疗用于II期子宫内膜癌女性

Multi-institutional Analysis of Vaginal Brachytherapy Alone for Women With Stage II Endometrial Carcinoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-04-24

该多机构汇总分析纳入106例FIGO II期子宫内膜样子宫内膜癌术后患者,其中92例接受单纯阴道近距离放疗(VBT)、14例接受VBT联合化疗,中位随访39.0个月。单纯VBT组5年阴道失败率2.6%、盆腔淋巴结失败率4.2%、远处转移率7.2%,5年无进展生存率74.0%、总生存率76.2%。作者认为,对1或2级、镜下宫颈间质浸润且行盆腔淋巴结清扫的选择性患者,考虑单纯辅助VBT是合理的。

要点

  • 106例FIGO II期子宫内膜样子宫内膜癌患者中,92例接受单纯VBT,14例接受VBT联合化疗。
  • 单纯VBT组5年阴道失败率2.6%、盆腔淋巴结失败率4.2%、远处转移率7.2%。
  • 作者认为对1或2级、镜下宫颈间质浸润且行盆腔淋巴结清扫的选择性患者,考虑单纯辅助VBT是合理的。

核心结论

  • 在接受单纯辅助VBT而未行外照射放疗的FIGO II期选择性患者中,阴道和盆腔失败率较低。
  • 作者认为,对1或2级疾病、镜下宫颈间质浸润且接受盆腔淋巴结清扫的选择性患者,考虑单纯辅助VBT是合理的。

研究设计与样本

  • 多机构汇总分析,纳入经手术分期的FIGO II期子宫内膜样子宫内膜癌患者,接受单纯VBT治疗。
  • 共纳入106例患者,其中92例接受单纯VBT、14例接受VBT联合化疗,中位随访39.0个月。
  • 采用单因素和多因素脆弱模型生存分析评估复发和死亡的临床病理危险因素。

主要发现

  • 盆腔淋巴结清扫在89.6%的患者中施行。
  • 104例(98.1%)为镜下宫颈间质浸润,2例(1.9%)为肉眼宫颈间质浸润。
  • 1或2级疾病占88.6%。
  • 单纯VBT未联合化疗组5年阴道失败率2.6%、盆腔淋巴结失败率4.2%、远处转移率7.2%。
  • 单纯VBT未联合化疗组5年无进展生存率74.0%、总生存率76.2%。

临床怎么用

  • 作者认为,对1或2级疾病、镜下宫颈间质浸润且接受盆腔淋巴结清扫的选择性II期患者,考虑单纯辅助VBT是合理的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the survival endpoints in women with International Federation of Gynecology and Obstetrics (FIGO) stage II endometrial cancer who received adjuvant vaginal brachytherapy (VBT) alone using multi-institutional pooled data. METHODS AND MATERIALS: We performed a multi-institutional analysis of surgically staged patients with FIGO stage II endometrioid-type endometrial cancer treated with VBT alone. Patient, tumor, and treatment characteristics were collected and analyzed. Univariable and multivariable frailty survival models were performed to assess clinicopathologic risk factors for recurrence and death. RESULTS: One hundred six patients were included (92 VBT alone and 14 VBT with chemotherapy) with median follow-up of 39.0 months. Pelvic node dissection was performed in 89.6% of patients. One hundred four patients (98.1%) and 2 patients (1.9%) had microscopic and macroscopic cervical stromal invasion, respectively. Grade 1 or 2 disease occurred in 88.6% of patients. For patients treated with VBT without chemotherapy, the 5-year estimates of vaginal failure, pelvic nodal failure, and distant metastases were 2.6%, 4.2%, and 7.2%, respectively. Five-year progression-free survival and overall survival were 74.0% and 76.2%, respectively. On univariable and multivariable models for progression-free survival, increasing age and lack of pelvic node resection were hazardous (P < .05). CONCLUSIONS: Vaginal and pelvic failure rates were low in this selected population of stage II patients receiving adjuvant VBT without external beam radiation therapy. It is reasonable to consider adjuvant VBT alone in selected patients with grade 1 or 2 disease and microscopic cervical stromal invasion who underwent pelvic lymphadenectomy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Harkenrider MM, Martin B, Nieto K, et al. Multi-institutional Analysis of Vaginal Brachytherapy Alone for Women With Stage II Endometrial Carcinoma. Int J Radiat Oncol Biol Phys. 2018. PMID: 29885996. doi:10.1016/j.ijrobp.2018.04.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。